Analyst Downgrades for Friday: Keysight, Akero Therapeutics, and More

Wall Street analysts have downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.

September 12, 2025

Wall Street analysts have recently downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.

HC Wainwright & Co. analyst Andrew S. Fein downgraded Akero Therapeutics, Inc. (NASDAQ:AKRO) from Buy to Neutral and cut the price target from $72 to $54. This move comes amidst the announcement of Novo Nordisk's acquisition of Akero for up to $5.2 billion, which could impact the stock's valuation Novo Nordisk to acquire Akero Therapeutics in $5.2 billion deal^[2].

Jefferies analyst Joseph Dickerson downgraded the rating for HSBC Holdings plc (NYSE:HSBC) from Buy to Hold. The downgrade reflects concerns about the bank's growth prospects and valuation multiples This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday^[1].

JP Morgan analyst Alexei Gogolev downgraded Doximity, Inc. (NYSE:DOCS) from Neutral to Underweight and announced a $62 price target. The downgrade is attributed to concerns about the company's growth prospects and valuation This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday^[1].

Morgan Stanley analyst Meta Marshall downgraded Keysight Technologies, Inc. (NYSE:KEYS) from Overweight to Equal-Weight and maintained the price target of $180. The downgrade indicates a change in the analyst's view on the company's growth prospects This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday^[1].

JP Morgan analyst Brian Cheng downgraded Allogene Therapeutics, Inc. (NASDAQ:ALLO) from Neutral to Underweight. The downgrade is driven by concerns about the company's growth prospects and valuation This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday^[1].

These downgrades highlight the evolving views of Wall Street analysts on several key companies. Investors should closely monitor these developments and consider the implications for their portfolios.